CAJ | 학술논문

目的探讨表浅性膀胱癌患者行经尿道膀胱肿瘤电切术(TURBT)后灌注膀胱化疗药物盐酸吡柔比星(THP)、羟基喜树碱(HCPT)或序贯灌注THP+ HCPT序贯灌注用于防治术后复发的疗效.方法应用THP、HCPT及THP+ HCPT序贯法组合行TURBT后膀胱内灌注,长期随访患者资料,观测其在0.5、1、2、3、4、5年时的肿瘤复发率.结果随访术后3～60个月.THP、HCPT、序贯组和对照组患者在6个月内复发率分别为4例(8.2％)、3例(7.3％)、1例(2.5％)和4例(19.0％)；1年内复发率分别为5例(10.2％)、4例(9.8％)、2例(5.0％)和9例(42.9％)；2年内复发率分别为7例(14.3％)、6例(14.6％)、2例(5.0％)和11例(52.4％)；3年内复发率分别为9例(18.4％)、9例(22.0％)、4例(10.0％)和12例(57.1％)；4年内复发率分别为11例(22.5％)、10例(24.4％)、6例(15.0％)和14例(66.7％)；5年内复发率为12例(24.3％)、11例(26.8％)、7例(17.5％)和15例(71.4％).结论浅表膀胱癌在TURBT后行膀胱腔内序贯灌注THP+ HCPT疗法预防膀胱癌术后复发疗效确定,较单用THP或HCPT复发率低,毒副作用无差异.是更有效的膀胱灌注疗法.
목적 탐토표천성방광암환자행경뇨도방광종류전절술(TURBT)후관주방광화료약물염산필유비성(THP)、간기희수감(HCPT)혹서관관주THP+ HCPT서관관주용우방치술후복발적료효.방법 응용THP、HCPT급THP+ HCPT서관법조합행TURBT후방광내관주,장기수방환자자료,관측기재0.5、1、2、3、4、5년시적종류복발솔.결과 수방술후3～60개월.THP、HCPT、서관조화대조조환자재6개월내복발솔분별위4례(8.2％)、3례(7.3％)、1례(2.5％)화4례(19.0％)；1년내복발솔분별위5례(10.2％)、4례(9.8％)、2례(5.0％)화9례(42.9％)；2년내복발솔분별위7례(14.3％)、6례(14.6％)、2례(5.0％)화11례(52.4％)；3년내복발솔분별위9례(18.4％)、9례(22.0％)、4례(10.0％)화12례(57.1％)；4년내복발솔분별위11례(22.5％)、10례(24.4％)、6례(15.0％)화14례(66.7％)；5년내복발솔위12례(24.3％)、11례(26.8％)、7례(17.5％)화15례(71.4％).결론 천표방광암재TURBT후행방광강내서관관주THP+ HCPT요법예방방광암술후복발료효학정,교단용THP혹HCPT복발솔저,독부작용무차이.시경유효적방광관주요법.
Objectives To investigate the efficacy and safety of intravesical instillation of pirarubicin hydrochloride(THP),hydroxycamptothecine(HCPT) or THP associated with HCPT after Transurethral Resection of Bladder Tumors(TURBT) for the treatment of Superficial Bladder cancer.Methods From Jan.2003 to Oct.2010,a total of 111 patients with newly diagnosed superficial bladder cancer undergone TURBT.The intravesical instillation of THP,HCPT,THP associated with HCPT and control was in 49,41,40 and 21 patients with bladder cancer after TURBT.The patients were received cystoscopy examination periodically to observe the recurrence rate at 0.5,1,2,3,4 and 5 years.Results The patients were followed up for 3 to 60 months,the 0.5 - year recurrence rate of the patients in the THP group,HCPT group,THP associated with HCPT and control group were 8.2％,7.3％,2.5％ and 19.0％,the 1 - year recurrence rate were 10.2％,9.8％,5％ and 42.9％,the2 - year recurrence rate were 14.3％,14.6％,5％ and 52.4％,the 3 - year recurrence rate were 18.4％,22.0％,10％ and 57.1％,the 4 - year recurrence rate were 22.5％,24.4％,15％ and 66.7％,and the 5 - year recurrence rate were 24.3％,26.8％,17.5％ and 71.4％ respectivelyConclusions The intravescal instillaton of THP associated with HCPT is an effective and safe treatment for superficial bladder cancer.It may be a potential better method of intravescial instillation of bladder cancer.